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The Cytoplasmic Terminus of Kaposi’s Sarcoma-Associated
Herpesvirus Glycoprotein B Is Not Essential for Virion
Egress and Infectivity䌤
R. Subramanian,1,2 O. D’Auvergne,1,2 Haixia Kong,2 and K. G. Kousoulas2*
Department of Biological Sciences, Southern University & A&M College, Baton Rouge, Louisiana,1 and Division of Biotechnology and
Molecular Medicine, School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana2

Kaposi’s sarcoma-associated herpesvirus (KSHV)-encoded glycoprotein B (gB) is an important determinant
of viral infectivity and virion egress. A small interfering RNA (siRNA)-based strategy was devised to inhibit
KSHV gB gene expression. Transient cotransfection of plasmids constitutively expressing gB and anti-gB
siRNAs in 293 cells substantially inhibited gB mRNA levels and protein production. Similarly, transient
expression of siRNAs into the primary effusion lymphoma cell line BCBL-1 caused a substantial reduction of
gB transcripts and protein synthesis. TaqMan real-time PCR assays against the lytic KSHV gene ORF59 and
infectivity assays on 293 cells were employed to assess the effect of inhibiting gB synthesis on virion egress from
BCBL-1 cells and infectivity on 293 cells, respectively. These experiments showed that gB was essential for
virion egress and infectivity. Transfection of a codon-optimized gB gene with the first 540 nucleotides altered,
and therefore not recognized by anti-gB siRNAs that target the native but not the codon-optimized sequence,
efficiently rescued virion egress and infectivity in BCBL-1 cells in the presence of siRNAs inhibiting wild-type
gB expression. To assess the role of the cytoplasmic domain of gB in virion egress, mutant gB genes were
generated specifying carboxyl terminal truncations of 25 and 58 amino acids disrupting two prominent
predicted ␣-helical domains associated with virus-induced cell fusion. A third truncation removed the entire
predicted cytoplasmic terminus of 84 amino acids, while a fourth truncation removed 110 amino acids,
including the terminal most hydrophobic, intramembrane anchoring sequence. Virion egress experiments
revealed that all truncated gBs facilitated virion egress from BCBL-1 cells, with the exception of the largest
110-amino-acid truncation, which removed the gB anchoring sequence. Importantly, the gB truncation that
removed the entire predicted cytoplasmic domain increased virion egress, suggesting the presence of a egress
regulation domain located proximal to the intramembrane sequence within the cytoplasmic domain of gB. All
supernatant virions were infectious on 293 cells, indicating that the carboxyl terminus of gB is not essential for
either virion egress or virus infectivity.
48), or via receptor-mediated endocytosis (61), as has been
shown for KSHV entry into human foreskin fibroblastic cells
and B cells (1, 3).
Herpesviruses assemble their capsids within the nuclei of
infected cells and most likely egress by an envelopment-deenvelopment process in which they acquire a primary envelope
from the inner lamellae of the nuclear membrane and subsequently de-envelop by fusion of their initial viral envelopes
with the outer nuclear lamellae, releasing capsids into the
cytoplasm. Final cytoplasmic envelopment is thought to occur
in the cytoplasm by the budding of cytoplasmic capsids into
intracellular membranes, most likely derived from the transGolgi network (37–39, 45). KSHV codes for a number of glycoproteins, some of which have significant homology to glycoproteins of other herpesviruses. These include glycoprotein B
(gB) (open reading frame 8 [ORF8]) (49), gH (ORF22), gM
(ORF39), gL (ORF47) (46, 59), and gN (ORF53) (14, 30, 59).
KSHV also encodes additional glycoproteins which do not
have homologs in other herpesviruses, including gpK8.1A,
gpK8.1B, K1, K14, and K15, which are expressed during lytic
replication (59).
gB is one of the most conserved herpesvirus glycoproteins. It
is an essential virion component for members of the alpha- and
betaherpesvirus subfamilies and thought to function in virion

Kaposi’s sarcoma-associated herpesvirus (KSHV), also referred to as human herpesvirus 8, is a member of the gamma2-herpesvirus family (genus Rhadinovirus) (46, 59). KSHV is
etiologically associated with Kaposi’s sarcoma, primary effusion or body cavity-based lymphoma, and multicentric Castleman’s disease (4, 21, 60). KSHV can infect a variety of human
cell types, including B, T, endothelial, epithelial, fibroblastic,
and keratinocyte cells, and nonhuman cell types, including owl
monkey kidney and baby hamster kidney fibroblastic cells (13,
15, 19, 20, 22, 28, 36, 43, 44, 50, 56, 62, 67). All herpesviruses
initiate infection by means of direct binding to various receptors on cell surfaces that is mediated by several viral glycoproteins embedded in viral envelopes. Viral glycoproteins play
important roles in virus attachment to susceptible cells, fusion
of the viral envelope with either cellular or endosomal membranes, and virion morphogenesis and egress (26, 42, 57). Herpesviruses enter into susceptible cells by direct fusion of viral
envelopes with cellular membranes via pH-independent or pHdependent processes, depending on the cell type (7, 16, 40, 47,
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attachment and virus entry into susceptible cells (10, 17, 52).
Epstein-Barr virus (EBV), a gamma-1-herpesvirus (genus
Lymphocryptovirus) (25), and murine gammaherpesvirus 68, a
member of the gamma-2-herpesvirus (genus Rhadinovirus)
subfamily, do not incorporate detectable levels of gB into their
virions (24). However, virions of bovine herpesvirus 4, a gamma2-herpesvirus (9, 34), contain gB (34). KSHV virions incorporate gB in the viral envelope, which is important for attachment to cell surfaces and entry via an RGD-dependent binding
to integrins. Initially, the ␣3␤1 integrin was implicated (2), but
more recently, it was shown that ␣V␤3 is the integrin involved
in gB RGD-mediated virus entry (23). KSHV gB is a type 1
membrane glycoprotein of 845 amino acids in length (6, 53,
55). It contains a predicted signal sequence of 23 amino acids,
an extracellular domain containing multiple glycosylation sites,
and multiple hydrophobic regions, of which the most carboxylterminal region serves to anchor gB in membranes (6, 53–55).
gB has been shown to be involved in the egress of herpesviruses, such as alphaherpesvirus, pseudorabies virus, and EBV
(8, 29, 32, 51, 52). KSHV gB was also shown to be essential for
virion egress in 293 cells, since a KSHV mutant virus carrying
a deletion of the gB gene was unable to egress from 293T cells,
while the defect was rescued by exogenously provided gB (31).
In contrast to these examples, herpes simplex virus type 1
(HSV-1) gB is not required for virion egress (11). More recently, however, it was shown that that the carboxyl terminus of
HSV-1 gB is ubiquitinated and it appears to regulate virion
egress (12).
RNA interference (RNAi) is the process by which doublestranded RNA silences gene expression, either by inducing the
sequence-specific degradation of complementary mRNA or by
inhibiting translation (41). Chemically synthesized short double-stranded RNA molecules of 21 or 22 nucleotides known as
small interfering RNAs (siRNAs) were shown to cause mRNA
degradation via the RNAi mechanism while evading the interferon response (18). Furthermore, endogenous expression of
siRNA in the form of short hairpin RNAs, which bear a foldback stem-loop structure (8–11), induced target gene silencing
in mammalian cells. RNAi and siRNA technologies have been
instrumental as molecular biological tools for the silencing of
specific gene expression under a variety of experimental settings (27). For KSHV, siRNA approaches have been used to
investigate specific viral functions (64, 66).
We employed an siRNA approach to conditionally silence
KSHV gB gene expression in 293 and BCBL-1 cells. In this
system, rescue of gB synthesis was accomplished by providing
a synthetic gB with an altered DNA sequence which could not
be recognized by the anti-gB siRNAs. This siRNA-based conditional silencing system was utilized to investigate the role of
the cytoplasmic terminus of KSHV gB in virion egress. We
found that the carboxyl terminus of gB contains a domain that
regulates virion egress, but overall, the cytoplasmic domain of
gB is not essential either for virion egress from BCBL-1 cells or
for virus infectivity.
MATERIALS AND METHODS
Cells and virus propagation. BCBL-1 cells harboring the rKSHV.152 genome
constitutively expressing the green fluorescent protein (GFP) (gift from J.
Vieira) were cultured in RPMI 1640 (Hyclone) medium with 10% heat-inactivated fetal bovine serum (Hyclone) with 2 mM L-glutamine, 1% penicillin-
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streptomycin (Gibco), and 250 mg of G418/ml (Gibco). 293A cells (ATCC) were
cultured in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum
and 1% penicillin-streptomycin. The KSHV lytic cycle was induced in the
BCBL-1 cells by adding 25 ng/ml of 12-O-tetradecanoylphorbol-13-acetate
(TPA; Sigma, St. Louis, MO). Virus from the supernatant was collected after
16 h and treated with DNase I before the extraction of viral DNA as previously
described (35). For infectivity studies, the supernatants were collected 48 h after
induction with TPA.
Antibodies. Rabbit polyclonal antibodies generated in our laboratory against
KSHV gB peptides were used to detect gB protein by Western blot analysis as
previously described (6). Peptide antibodies specific to amino acids 167 to 191 of
the gB protein were used in this study. Mouse anti-HuGAPDH (human glyceraldehyde-3-phosphate dehydrogenase) monoclonal antibodies were used to detect the GAPDH.
Vector construction. SiRNAs were designed targeting the 5⬘ region of the
KSHV gB expression sequence by use of Ambion’s online siRNA target
finder. Two siRNAs, si18 (sense strand, HindIII [5⬘ AGCTTCAAGTATGA
ACTCCCGAGATTCAAGAGATCTCGGGAGTTCATACTTGTTG 3⬘]; antisense strand, EcoRI [5⬘-AATTCAACAAGTATGAACTCCCGAGATCTC
TTGAATCTCGGGAGTTCATACTTGA-3⬘]), located starting at nucleotide
403 after the ATG codon, and si22 (sense strand, HindIII [5⬘AGCTTGGT
AAATGTCAACGGGGTATTCAAGAGATACCCCGTTGACATTTAC
CTTG 3⬘]; antisense strand, EcoRI [5⬘-AATTCAAGGTAAATGTCAACGG
GGTATCTCTTGAATACCCCGTTGACATTTACCA-3⬘]), located starting
at 484 bases from the ATG codon, were selected among 25 siRNAs against
gB. The siRNAs contained HindIII and EcoRI overhangs at the 5⬘ and 3⬘
ends, respectively, for cloning purposes. Equimolar concentrations of the
individual strands of siRNAs were mixed, denatured at 94°C for 5 min, and
allowed to cool down slowly to room temperature to allow annealing of the
two strands. The mixture was used for ligation into HindIII/EcoRI-digested
p3xFLAG vector by use of T4 DNA ligase (NEB, Inc.). Ligation mix was
transformed into one-shot TOP10 competent cells (Invitrogen) and selected
on LB agar plus 100 g/ml ampicillin. Recombinant clones were confirmed by
restriction analysis and nucleic acid sequencing.
Codon optimization and construction of gB truncations. The region consisting
of the first 540 bases of KSHV gB from ATG to the HpaI restriction site, which
carried the siRNA target sequences, was codon optimized using the DNAWorks
website at http://helixweb.nih.gov/dnaworks. The wild-type KSHV gB was cloned
in the expression vector p3xFLAG within the KpnI and BamHI sites. The
codon-optimized fragment was used to replace the first 540-bp region between
the KpnI and HpaI sites of the wild-type gB gene. The gB carboxyl-end truncations were generated by designing forward primers for the 5⬘ end of the codonoptimized gB and reverse primers carrying stop codons 75, 174, 252, and 330 bp
from the 3⬘ end of gB to generate truncation gBp, gBg, gBc, and gBtrm gene
constructs, respectively. The forward primers for codon-optimized gB and reverse primers carrying the opal mutations are indicated in Table 1. A 577-bp
encephalomyocarditis virus internal ribosome entry site (IRES) sequence was
inserted downstream of the siRNA in the p3xFLAG vector between the BglII
and EcoRV restriction sites. The codon-optimized gB gene sequences coding for
the gB truncations were cloned downstream of the IRES at the BamHI site.
Plasmid vectors expressed siRNA individually or in combination with any one of
the codon-optimized gBco, gBp, gBg, gBc, or gBtrm constructs.
Transient transfection of 293 and BCBL-1 cells. 293 cells were seeded onto
12-well plates at 0.5 ⫻ 105 cells/well for 8 hours, medium was replaced with 500
l of fresh medium, and cells were used for transfection experiments. BCBL-1
cells (0.5 ⫻ 105 cells/well) were suspended in fresh medium and used for each
transfection. Transfections were carried out using SuperFect (Qiagen, Inc.)
transfection agent according to the manufacturer’s instructions.
Immunohistochemical studies. To detect the expression of gB mutant genes,
293 cells were transiently transfected with plasmid vectors carrying gBco, gBp,
gBg, gBc, and gBtrm as described earlier. Forty-eight hours posttransfection, the
cells were fixed, reacted with anti-gB peptide antibody, and stained using
the Vector NovaRED substrate kit (Vector Laboratories Inc., California), as per
the manufacturer’s instructions.
RT-PCR. Transiently transfected 293 cells were harvested 48 h after transfection and total RNA was extracted. Specifically, medium was aspirated and cells
were scraped and resuspended evenly in 200 l of ice-cold phosphate-buffered
saline. Seven hundred microliters of Tri-Reagent (Molecular Research Center,
Inc.) was added to the cells and mixed thoroughly to lyse the cells. After 15 min,
200 l of chloroform was added and mixed thoroughly. The tubes were placed on
ice for 15 min and centrifuged at 13 ⫻ 103 rpm for 15 min at 4°C. The supernatant was collected, precipitated in an equal volume of isopropanol, and left on
ice for 30 min. The mix was centrifuged at 4°C for 20 min at 13 ⫻ 103 rpm. The
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TABLE 1. List of primers

Primer name (description)

Sequence (5⬘ 3 3⬘)

gBco (gB optimized; forward) ..........................................................................................ACAGCAAAGCTTATGACCCCCAGGAGCAGGCTG
gBp (25-aa gB truncation; reverse)..................................................................................TTGTATGGATCCTCATGCGGTACGCTGAAACACCGA
gBg (58-aa gB truncation; reverse) ..................................................................................ATAGAAGGATCCTCAGATTTCCTCCCGTGTTGGGGC
gBc (84-aa gB truncation; reverse) ..................................................................................GGATCCTCTTCACTCACGCCTGGGCTA
gBtrm (110-aa gB truncation; reverse)............................................................................GGATCCTCACATGCCACCTAGGGGGTGTTT
gBUNI (gB universal; forward)........................................................................................TCCAGACTACCCACGAGGAC
gBUNI (gB universal; reverse) .........................................................................................GTCAGGTTAATCGCGGACAT
gBwt (forward)....................................................................................................................GACACCTTTCAGACGT
gBwt (reverse).....................................................................................................................TCTCGGGAGTTCATACTTGT
gB (carboxy; forward) ........................................................................................................ATCGTTATAGCAATCATC
gB (carboxy; reverse) .........................................................................................................TCACTCCCCCGTTTCCGG
ORF59 (forward) ...............................................................................................................TCAGCTTCAGGAATACGTCCG
ORF59 (reverse) ................................................................................................................GGCTATGCCAGCGTCGAGTA
ORF59 (probe)...................................................................................................................FAMa-CGCGTGAGCTATTCGGTGCGAATA-TAMRA
GAPDH (forward) .............................................................................................................GATTCCACCCATGGCAAATT
GAPDH (reverse) ..............................................................................................................AAGATGGTGATGGGATTTCCATT
FAM, 6-carboxyfluorescein.

resultant pellet was washed in 70% ethanol made with nuclease-free water, dried,
and resuspended in 40 l of nuclease-free water. The RNA was treated with
Turbo DNase I (Ambion, Inc.) and quantified. First-strand cDNA was made
using the high-capacity cDNA reverse transcription (RT) kit (Applied Biosystems, Inc.). Equal quantities of first-strand cDNA were used for PCR using the
universal gB primers and the primers for GAPDH. The PCR products were
resolved by electrophoresis on a 1% agarose gel.
For RT-PCR quantification of RNA derived from BCBL-1 cells, lytic replication of KSHV was induced by adding 25 ng/ml TPA to transiently transfected
BCBL-1 cells 24 h after transfection. Induction was carried out in serum-free
medium and the supernatant and cells were collected 16 h postinduction. Harvested cells were resuspended in 500 l of ice-cold phosphate-buffered saline and
split into two parts for RNA extraction (200 l) and Western blot analysis (300
l). Total RNA was extracted and first-strand cDNA was prepared as described
earlier. Equal amounts of first-strand cDNA were used for PCR using the
universal gB primers and the primers for GAPDH (Table 1) in the case of 293
cells. RT-PCR of RNA derived from BCBL-1 cells was carried out using primers
specific to full-length wild-type gB and the carboxyl-terminal region of gB (Table
1) in addition to primers for universal gB and GAPDH. The PCR products were
resolved by electrophoresis on a 1% agarose gel.
Western blot analysis. The 293 or BCBL-1 cells were pelleted and resuspended in 100 l of radioimmunoprecipitation assay lysis buffer and sonicated at
15% strength for 15 seconds. Cell debris was pelleted at 14,000 rpm for 10 min
at 4°C and the total soluble protein (TSP) was transferred to a fresh tube and
quantified using the bicinchoninic acid kit (Pierce Biotechnology, Inc.). Fifteen
micrograms of TSP from each sample was loaded on a 10% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis gel and resolved by electrophoresis.
The proteins were transferred onto a nitrocellulose membrane and used for
Western blot analysis. Rabbit polyclonal anti-gB and mouse monoclonal antiGAPDH antibodies were used as primary antibodies. Horseradish peroxidasetagged anti-rabbit/anti-mouse antibodies were used as secondary antibodies.
ECL substrate (Amersham Biosciences) was used for chemiluminescent detection of proteins.
TaqMan real-time PCR analysis. Real-time PCR was carried out on viral
DNA from supernatants of BCBL-1 cells essentially as described previously (35).
Specifically, the primers and probe (6-carboxytetramethylrhodamine [TAMRA])
for the real-time PCR were designed to detect ORF59 (Table 1). Supernatants
were collected 16 h after lytic cycle induction and 200 l was used for the
extraction of viral DNA. The supernatants were treated with Turbo DNase I
(Ambion, Inc.) for 2 h at 37°C. Viral DNA was extracted using the DNeasy blood
and tissue kit (Qiagen, Inc.) as per the manufacturer’s instructions. Equal volumes of viral DNA were used for TaqMan PCR analysis. Purified KSHV bacterial artificial chromosome 36 (BAC 36) DNA was used to generate the standard curve.
Infectivity of BCBL-1 supernatants on 293 cells. Supernatants of BCBL-1 cells
containing infectious virions were collected after TPA induction of viral replication for 48 h. 293 cells seeded at 75% confluence in 12-well plates were
infected with BCBL-1 supernatants by use of 2 g/ml Polybrene. The number of
infected cells was visualized by counting 293 cells expressing enhanced GFP
(EGFP) by use of a fluorescence microscope at 48 h postinfection. Infection was

quantified by counting the number of infected cells in three different 10⫻ viewing
fields and calculating the mean value. The process was repeated for all tissue
culture wells. The experiment was repeated three times.

RESULTS
Construction and testing of a conditional silencing system
for KSHV gB expression. The siRNAs si18 and si22, which
target gB mRNA sequences starting at nucleotides 403 and
484, respectively (Fig. 1A), were designed as described in Materials and Methods. These two siRNAs were selected from a
list of more than 25 siRNAs based on their specificity for the
KSHV gB mRNA after extensive homology searches using
BLAST and CLUSTALX algorithms. To develop conditional
inhibition of gB expression using the si18 and si22 siRNAs, the
first 540 bp of the DNA coding sequence of gB was codon
optimized as described in Materials and Methods. Codon optimization substantially altered the 5⬘-most DNA sequence of
the gB gene, effectively destroying recognition of the codonoptimized gB mRNA by the si18 and si22 siRNAs, while the
encoded amino acid sequence was unaltered (Fig. 1B). The
wild-type KSHV gB (gBw) and the codon-optimized gB (gBco)
were cloned into plasmid p3xFLAG (Sigma, Inc.) The siRNAs
si18 and si22 were cloned either individually in the 3⫻FLAG
plasmid (psi18, psi22) or together in tandem with the gBco
gene separated by a 577-bp encephalomyocarditis virus IRES
situated immediately downstream from the siRNA sequences
(psi18/22gBco) (see Materials and Methods).
Conditional silencing of gB expression was tested in transient expression experiments with 293 cells. Cells were cotransfected with mixtures of plasmids containing gBw mixed with
either psi18 or psi22 or with an equimolar mixture of plasmids
containing gBco with either psi18 or psi22 plasmids. RT-PCR
analysis using primers which are equally specific for gBw and
gBco (universal gB primers; gBUNI) showed a significant reduction in the levels of gB transcripts in 293 cells cotransfected
with wild-type gB and siRNAs 18 and 22, as also evidenced
after densitometric analysis using levels of GAPDH transcripts
for normalization purposes (Fig. 2). In contrast, cotransfection
of gBco with either psi18 or psi22 did not reduce the levels of
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gB transcripts (Fig. 2). gB transcripts were not detected in
RNA derived from untransfected 293 cells or cells transfected
with the transfecting agent alone (Fig. 2). Both gBw and gBco
appeared to produce similar amounts of gB transcripts in the

FIG. 2. RT-PCR analysis for detection of gB mRNA in transiently transfected 293 cells. 293 cells were either transfected with plasmid vectors expressing wild-type gB individually or cotransfected with vectors expressing
siRNA and codon-optimized gB. RT-PCR was carried out using primers
specific to gB (universal gB primers; 250 bp) and GAPDH primers, producing an 80-bp amplicon. cDNA from 293 cells and 293 cells transfected with
SuperFect were used as controls. Additional controls included 293 cells cotransfected with vectors expressing either wild-type gB and nonspecific
siRNA or codon-optimized gB (gBco) and nonspecific siRNA. The levels of
gB transcripts obtained after densitometric analysis and normalization with
GAPDH are shown aligned below for each sample.

presence of a nonspecific siRNA provided for control purposes
(Fig. 2).
Similar experiments were performed as outlined above, with
the exception that cellular extracts were processed to detect gB
expression in Western blots. gB expression was quantified by
densitometry and normalized to GAPDH protein levels. Significant inhibition of gB expression was observed for 293 cells
cotransfected with plasmids expressing gBw and either si18 or
si22 in comparison to cells transfected with gBw and a nonspecific siRNA (Fig. 3). In contrast, the amount of gB detected
in samples derived from cotransfections of 293 cells with gBco
and either si18 or si22 was similar to that seen for gB from cells
cotransfected with gBco and the nonspecific siRNA, indicating
that the siRNAs did not inhibit gBco expression (Fig. 3).
Role of the carboxyl terminus of gB in virion egress from
BCBL-1 cells. To investigate the role of the carboxyl terminus
of gB in virion egress, a panel of mutated gB genes was constructed, specifying different gB truncations by using the gBco
gene as the template for mutagenesis. The carboxyl terminus of
gB was truncated at specific sites to disrupt predicted ␣-helical
structures (Fig. 4). The gB truncations include gBp, which has
25 amino acids deleted; gBg, with a deletion of 58 amino acids;
gBc, with 84 amino acids deleted; and gBtrm, with 110 amino
acids deleted. gBp disrupts the predicted ␣-helical domain ␣1,
while the gBg truncation disrupts the predicted ␣-helical domain ␣2. gBc removed the entire predicted cytoplasmic domain of gB, while gBtrm removed the entire carboxyl terminus,
including part of the predicted transmembrane domain (Fig.
4). Plasmids coding for the gB truncations were transfected
into 293 cells and gBs were detected by immunohistochemistry.
All gB constructs, including the gBco full-copy gB, were detected by anti-gB antibodies, except for gBtrm, which was not
detectable (Fig. 5). Low levels of gBtrm were detected in
supernatants of infected cells, suggesting that gBtrm was secreted into extracellular spaces (not shown).
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FIG. 1. Schematic representation of gB- and siRNA-expressing gene cassettes. (A) Schematic representation of the KSHV gB showing the position
of the siRNA target sequences on the wild-type gB and the codon-optimized gB portion. The codon-optimized fragment replacing 540 bp in the 5⬘ end
between Kpn1 and Hpa1 is shown as a light-shaded area of the gB gene. (B) Schematic of the siRNA gene expression cassette containing the siRNA
(dark-shaded box) and gB genes separated by an IRES. The approximate locations of the different gB truncations are shown. The three different
amplimers used for diagnostic PCR are indicated by light-shaded areas bracketed by PCR primers (arrows). CMV, cytomegalovirus.
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FIG. 3. Western blot analysis for detection of gB protein in transiently
transfected 293 cells. (A) 293 cells either transfected with plasmid vectors
expressing wild-type gB individually or cotransfected with vectors expressing siRNA and codon-optimized gB. TSP was extracted and used for
Western blot analysis. Rabbit anti-gB antibodies were used to detect the
75-kDa gB protein species and mouse anti-HuGAPDH was used to detect
GAPDH protein for normalization purposes. TSP from 293 cells and TSP
from 293 cells transfected with SuperFect were used as controls. Additional controls included samples derived from 293 cells cotransfected with
plasmid vectors expressing either wild-type gB and nonspecific siRNA or
codon-optimized gB (gBco) and nonspecific siRNA. The levels of gB
protein obtained after densitometric analysis of Western immunoblots
and normalization with GAPDH protein are shown aligned below for
each sample. ␣-, anti-.

J. VIROL.

To investigate the ability of si18 and si22 siRNAs to inhibit
gB expression in BCBL-1 cells, similar experiments were performed as outlined earlier for the transient expression experiments with 293 cells by use of RT-PCR to detect gB mRNAs
and GAPDH for normalization purposes. In these experiments, BCBL-1 cells were transfected and 24 h posttransfection cells were induced with TPA as detailed in Materials and
Methods. Transfection of psi18 or psi22 in BCBL-1 cells significantly reduced endogenous gBwt mRNA levels detected by
RT-PCR using primers that amplify a 338-bp gBwt-specific
DNA fragment in comparison to what was seen for transfection with the nonspecific siRNA (Fig. 6A). In contrast, in
BCBL-1 cells transfected with plasmids psi18gBco and
psi22gBco, which coexpress the codon-optimized gB with si18
and si22, respectively, gB levels were approximately the same
as those detected for BCBL-1 cells transfected with the nonspecific siRNA (Fig. 6B). RT-PCR products shown in the row
labeled gBUNI were produced using gB primers, which amplify a 240-bp DNA fragment situated outside the codon-optimized region of gBco and are therefore predicted to amplify
both gBwt and gBco sequences with equal efficiency.
Similar transfection experiments were performed with each
of the gB constructs encoding carboxyl-terminal truncations of
gB. Coexpression of gBp, gBg, gBc, and gBtrm with plasmids
expressing either si18 or si22 elevated gB expression in
BCBL-1 cells to levels similar to those observed for BCBL-1
cells transfected with the nonspecific siRNA (Fig. 6B). As
expected, PCR primers which specifically amplify a 317-bp
DNA fragment encoding the gB carboxyl terminus did not
detect the elevated levels of the truncated gB transcripts ob-

FIG. 4. Schematic diagram showing the predicted secondary structure of the KSHV gB carboxy-terminal cytoplasmic domain. The positions of
the four truncations, namely, gBp, gBg, gBc, and gBtrm, are indicated.
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served with the universal gB primers, because the targeted gB
gene sequence was absent from all gB mutant genes (Fig. 6C).
The amount of gB transcripts detected is similar to that observed for si18- or si22-inhibitory conditions (Fig. 6C).
Similar experiments were performed with BCBL-1 cells as
described above, with the exception that gB expression was
detected using Western blot assays. Transfection of BCBL-1
cells with either psi18 or psi22 plasmids reduced the amount of
gB detected using anti-gB specific antibody in comparison to
gB levels in cells transfected with the nonspecific siRNA (Fig.
7A and B). As observed previously for the gB mRNA levels,
coexpression of gBco, gBp, gBg, and gBc with plasmids expressing either si18 or si22 elevated gB expression in BCBL-1
cells to levels similar to those observed for BCBL-1 cells transfected with the nonspecific siRNA (Fig. 7A and B). Coexpression of gBtrm with either si18 or si22 did not elevate the overall
amount of gB expression, as noted previously for the transient
transfection experiments with 293 cells (Fig. 7A and B).
It has been previously shown that gB is essential for virion
egress from 293 cells (31). Therefore, we investigated whether
the inhibition of gB mRNA levels by the si18 and si22 siRNAs
could reduce the amount of virion particles in the supernates
of BCBL-1 cells. The number of virion particles in the supernates of BCBL-1 cells was quantified by real-time TaqMan
PCR after DNase treatment of extracellular virions to specifically detect fully encapsidated viral DNA, as described above
(see Materials and Methods) and previously (35). Transfection
of BCBL-1 cells with either si18- or si22-expressing plasmids
substantially reduced the amount of viral genomes detected in
the supernates of BCBL-1 cells (Fig. 8). Coexpression of gBco
with either si18 or si22 rescued virion egress to levels similar to
those observed for BCBL-1 cells transfected with the nonspecific siRNA (Fig. 8). Coexpression of the gBp and gBg truncations with either si18 or si22 rescued virion egress to a level
similar to that observed for the nonspecific siRNA control
sample, with the exception of the gBtrm (Fig. 8). In contrast,

coexpression of the gBc truncation with either si18 or si22
reproducibly increased virion egress by nearly 20% in comparison to what was seen for the nonspecific siRNA control sample, while coexpression of gBtrm with either si18 or si22 failed
to rescue virion egress (Fig. 8).
To determine the effect of the gB truncations on virion
infectivity, supernatant virions were used to infected 293 cells.
Infectivity was assayed by the expression of the EGFP gene,
which is constitutively expressed by the rKSHV.152 genome
(62). These results showed a correlation between the numbers
of virion particles and infectious virions found in the supernatants of BCBL-1, revealing that all truncated gBs were able to
increase production of infectious virions in the supernatants of
BCBL-1 cells, with the exception of the gBtrm-transfected
BCBL-1 cells (Fig. 9A and B).

DISCUSSION
The cloning of the KSHV genome as a BAC has enabled the
rapid generation of KSHV mutant viruses (22, 67, 68). Virus
mutants lacking specific gene functions have been generated
and characterized in cell culture systems permissive for viral
replication (31, 35, 65, 68). However, viral yields from cells
transfected with KSHV mutant genomes are relatively low,
hindering the elucidation of gene functions involved in virion
infectivity, assembly, and egress from infected cells. In this
study, we utilized anti-gB siRNAs to inhibit gB synthesis in
BCBL-1 cells, which are known to produce large amounts of
infectious virions after induction of the dormant KSHV genome to lytic replication. Transfection of BCBL-1 cells under
anti-native gB siRNA conditions with a codon-optimized gB
not susceptible to siRNA inhibition restored gB expression to
near-native levels. We utilized this system to demonstrate that
the cytoplasmic terminus of gB from amino acid residues 761
to 787 contains a domain that regulates virion egress; overall,
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FIG. 5. Immunohistochemistry for detecting expression of gB mutants in 293 cells. Anti-gB antibodies were utilized to detect gB expression in
transiently transfected cells at 48 h posttransfection as described in Materials and Methods.
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FIG. 6. Detection of gB mRNA in BCBL-1 cells. Total RNA was extracted from transiently transfected BCBL-1 cells and first-strand cDNA
was used for PCR using primers. Shown are wild-type gB (gBwt) (A), universal gB primers amplifying both wild-type and codon-optimized gB
(gBUNI) (B), and gB carboxy primers amplifying the 3⬘ end of gB (gBCarb) (C) and GAPDH primers producing an 80-bp amplicon. The levels
of gB transcripts obtained after densitometric analysis and normalization with GAPDH are shown aligned below for each sample.
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however, this domain is not essential for either virion egress or
infectivity.
Transient expression of either si18 or si22 siRNAs reduced
gB mRNA levels and gB expression in both 293 and BCBL-1
cells by approximately 40 to 60%. Typically, more than 40% of
293 cells can be routinely transfected with plasmids by use of
SuperFect (Qiagen, Inc.), as evidenced by transfection rates
obtained with an EGFP-expressing plasmid (not shown).
Therefore, the observed siRNA-mediated inhibition of mRNA

levels and gB expression indicates that the majority of the 293
cells were cotransfected with both siRNA- and gBw-expressing
plasmids. In BCBL-1 cells, approximately 20% of the cells can
be routinely transfected with an indicator EGFP-expressing
plasmid. Furthermore, approximately 15% of BCBL-1 cells
can be reproducibly induced to KSHV lytic gene expression
after induction with TPA (not shown). Therefore, if the transfection rate of BCBL-1 cells is independent of the rate of
KSHV lytic gene expression, only 3% of BCBL-1 cells could be

FIG. 8. Determination of virion egress by use of real-time PCR. Transiently transfected BCBL-1 cells were induced with 25 ng/ml TPA for 12 h
in serum-free medium. Two hundred microliters of supernatant was collected and treated with Turbo DNase for 2 h. Viral DNA was extracted
from equal volumes of supernatants by use of a DNeasy tissue and blood kit and used for real-time PCR with primers for ORF59 and the
6-carboxyfluorescein/TAMRA TaqMan probe (Table 1). Serial dilutions of BAC 36 plasmid containing the wild-type KSHV genome were used
to generate the standard curve.
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FIG. 7. Western blot analysis for detection of gB in transiently transfected BCBL-1 cells. (A) Cells were transfected with plasmid vectors
expressing si18 and various gB genes as indicated. (B) Cells were transfected with plasmid vectors expressing si22 and various gB genes as indicated.
The levels of gB protein detected by Western immunoblot analysis and quantified by densitometric analysis and normalization with GAPDH
protein are shown aligned below for each sample.
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FIG. 9. Determination of infectious virions in BCBL-1 supernatants. (A) Supernatant virus from transiently transfected BCBL-1 cells was
collected 48 h postinduction with TPA and used to infect 293 cells. Infected cells were visualized with a fluorescence microscope. (B) The average
numbers of GFP-positive 293 cells in three different fields of visualization were determined.

both transfected and induced to lytic gene expression. However, gB mRNA levels were reduced by 40 to 60%, and gB
synthesis was reduced by more than 30%, indicating that a
disproportionate number of BCBL-1 cells were both transfected and reactivated. Recently, it was shown that BCBL-1
cells in the S phase appeared to be more likely to undergo lytic
reactivation than were those in G0/G1 phase, and these cells
exhibited a smooth surface topology in comparison to the G0/
G1-phase cells (63). Therefore, it is possible that BCBL-1 cells
in the S phase may be more amenable to transfection using
SuperFect (Qiagen, Inc.), accounting for the observed inhibition of gB mRNA levels and gB expression. Cotransfection
with the codon-optimized gB, which was not susceptible to
siRNA inhibition, effectively increased gB mRNA levels and
gB expression. In these experiments, the siRNAs were cloned
in tandem with the codon-optimized gB, which ensured their
coexpression into the same transfected 293 and BCBL-1 cells.
As discussed earlier, similar arguments can be made to explain
the observed recovery of gB mRNA levels and gB synthesis
encoded by the codon-optimized gB constructs.

Earlier studies established that KSHV gB was essential for
KSHV egress from 293 cells. In these studies, the KSHV gB
gene was deleted via mutagenesis of the KSHV BAC pBAC36.
Lack of gB led to inhibition of virion egress, while complementation of gB expression by transient expression of plasmids
coding for gB recovered virion egress (31). Our results with
BCBL-1 cells are in agreement with these published studies
and suggest that egress pathways in 293 and BCBL-1 cells are
similar with respect to gB functions in virion egress. Complementation of BCBL-1 cells with truncated gBs revealed that
the cytoplasmic carboxyl terminus of gB was not essential for
either virion egress or virus infectivity. Furthermore, it appeared that the cytoplasmic terminus contained a domain located proximal to the predicted intramembrane region that
regulated virion egress, since deletion of the entire gB cytoplasmic domain significantly increased virion egress in comparison to what was seen for the shorter gB truncations. It is
possible that the long carboxyl terminus of KSHV gB may bind
to one or more other viral proteins and that this binding may
affect the rate of cytoplasmic envelopment and virion egress.
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Apparently, gB functions in virion egress are not entirely conserved among different herpesviruses. For HSV-1, it was originally shown that gB is not essential for virion egress, since
virions devoid of gB could egress out of cells but were not
infectious (10). In contrast to these results, it was recently
shown that the cytoplasmic terminus of gB may be required for
efficient virion egress, since gB carboxyl-terminal truncations
appeared to reduce virion egress by two- to threefold. This
egress phenotype was attributed to the ubiquitination of the
cytoplasmic terminus of HSV-1 gB (12). gB has also been
shown to be essential for the egress of other herpesviruses,
such as pseudorabies virus and EBV (8, 29, 32, 51, 52).
The process of final virion envelopment most likely occurs in
the cytoplasm, and it is mediated by interactions between tegument proteins and the cytoplasmic termini of viral membrane
proteins and glycoproteins (37, 38). All gB homologs have a
rather large cytoplasmic domain ranging from 84 amino acids
for KSHV to 109 amino acids for HSV-1. The KSHV gB was
shown to interact with the ORF64 tegument protein, which
could facilitate virion envelopment and infectious virus production (58). Potential ubiquitination of the carboxyl terminus
of KSHV gB, as demonstrated for HSV-1 gB (12), or the
presence of arginine-rich regions, as demonstrated for EBV
(33), may affect intracellular transport and the localization of
KSHV gB within intracellular membranes, indirectly affecting
virion envelopment and egress.
All KSHV gB truncations with the exception of the largest
(110-amino-acid) truncation were able to complement virion
egress and virion infectivity under siRNA inhibitory conditions
for the endogenous wild-type gB, indicating that the cytoplasmic domain of gB is not essential for either function. In contrast, partial deletion of the cytoplasmic terminus of HSV-1 gB
increased virus-induced cell fusion, while larger deletions resulted in loss of viral infectivity (5). The cytoplasmic domains
of KSHV and HSV-1 gB are predicted to be 84 and 109 amino
acids, respectively. Despite their different amino acid lengths,
two prominent predicted ␣-helical domains appear to be topologically conserved within their cytoplasmic domains. Furthermore, it was shown that a deletion of 25 amino acids from
the KSHV gB terminus increased its ability to cause cell fusion
obtained after cotransfection with gH- and gL-expressing plasmids (54), in agreement with the results obtained with a similar
deletion in HSV-1 gB (5). Therefore, it appears that KSHV
and HSV-1 gBs have both conserved as well as divergent functions in gB-mediated cell fusion, virion assembly, egress, and
infectivity.
Overall, the results described herein suggest that KSHV gB
domains other than the cytoplasmic domain are involved in
virion egress and infectivity. It is likely that the absence of gB
may lead to altered conformations of membrane-bound proteins and glycoproteins that are directly involved in cytoplasmic virion envelopment and egress. In this regard, it is possible
that the intramembrane and extracytoplasmic domains of gB,
either separately or together, are involved in direct or indirect
interactions with membrane-bound proteins and glycoproteins
involved in cytoplasmic virion envelopment and egress. Additional experiments are required to delineate these functional
domains. The siRNA-mediated inhibition of KSHV gene synthesis described here provides an additional tool to investigate
the structure and function of individual viral proteins in the

7153

KSHV virus life cycle, especially in BCBL-1 cells. The observed high transfection efficiency of BCBL-1 cells induced to
lytic replication may enable the concurrent conditional silencing of multiple KSHV genes, enabling the dissection of potential cooperative functions in the KSHV life cycle and virusinduced tumorigenesis.
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